Navigation Links
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the expansion of its late-stage development leadership team with the appointment of industry veterans Steven B. Ketchum, Ph.D., as Senior Vice President, Research and Development and Mary G. Bolton, M.D., Ph.D., as Vice President, Clinical Development. In addition, Judith A. Fox, Ph.D., has been promoted to Vice President, Product and Preclinical Development and Glenn C. Michelson, M.D., has been promoted to Vice President, Clinical Strategy.

"As our lead anti-cancer product candidate, voreloxin, continues to demonstrate promising clinical activity and a consistent safety profile in both acute myeloid leukemia and ovarian cancer, we are excited to welcome Drs. Steve Ketchum and Mary Bolton to Sunesis," said Daniel Swisher, Sunesis' Chief Executive Officer. "We are also pleased to announce the promotions of Drs. Judy Fox and Glenn Michelson. Judy and Glenn have made tremendous contributions to our voreloxin development program. Collectively, the extensive product development and regulatory expertise of this expanded leadership team will be a tremendous asset as we prepare for the expected initiation of late-stage trials for voreloxin next year."

"With the promising clinical activity and safety profile seen to date for voreloxin, I am excited by the opportunity to lead Sunesis' talented development organization as we advance this first-in-class product candidate into its next phase of development," said Dr. Ketchum.

Dr. Ketchum brings more than fifteen years experience in late-stage product development and clinical regulatory strategy, having led the filings of multiple successful New Drug Applicati
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., December 2 Pepscan Holding NV,the Netherlands b...icking,technology for the generation of immune the...m E.M. Mol, Ph.D. as new Chief Executive Officer. ...ans corporate functions and,the overall management... to,Pepscan more than 20 years of management exper...
(Date:12/2/2009)... Pte Ltd today announced data presentations on its...n Society of Hematology 51st Annual Meeting and Ex... on the clinical results from the Phase 1 dose-esc...rability and pharmacokinetic/pharmacodynamic (PK/P...mg. These doses were administered once daily conti...
(Date:12/2/2009)...e-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZ...eutical company focused on endocrine therapy and o...ug Administration (FDA) has granted Fast Track des...tor compound, perifosine (KRX-0401), for the treat...x Biopharmaceuticals, Inc. ("Keryx") ( KERX), is A...
(Date:12/2/2009)...ing to the National Institute of Health, 40 percen...es already have some stage of diabetic retinopathy...ed by leaky blood vessels, is a major cause of bli...ost feared diabetic complications. In fact, up to...r 10 years or more will experience some form of di...
Breaking Biology Technology:Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...ility in identity theft cases was spelled out duri...e Conference, and healthcare providers got a real ...sing a hypothetical case of identity theft from an... & Friedrich demonstrated how much trouble health...n they take steps to prevent security breaches tha...
...tion system for boats and recreational vehicles. T... software for use by hikers, campers and sportsmen...ilking system that is healthier for cows, which, i...ry out "Wisconsin" to you, welcome to the third an...even finalists from 14 Wisconsin communities are e...
...e the wrong way, but he believes friction sometime...szewski as the state,s CIO in 2003 to bring greate... enterprise, and he certainly expected some bumps ...ive snags that some large-scale IT projects have e...ng target now pegged at $9 million annually - will...
Other Biology Technology:Managing the nightmare of identity theft 2Managing the nightmare of identity theft 3Managing the nightmare of identity theft 4Business plan contest finalists reflect state's economic character 2Business plan contest finalists reflect state's economic character 3Embattled state CIO stands his ground 2Embattled state CIO stands his ground 3
(Date:12/3/2009)...estment in energy efficient technologies research,...uncil (EPSRC) Chief Executive Dave Delpy believes ...esearch has already brought us fuel cells, marine,...nt is needed to develop the capabilities of differ...n targets by 2020 and limit the impact of climate ...
(Date:12/2/2009)... have a more difficult time quitting smoking than ...ut acculturation has no affect on Latinas odds of ...blished in Cancer Epidemiology, Biomarkers & Prev... Cancer Research. The December issue has a special...ng cessation differently for Latino men and women,...
(Date:12/2/2009)... exposed to cigarette smoking scenes in movies are...this may be part of the acculturation process asso...tudy findings. , "Our study supports an R-rating ...e global implementation of the World Health Organi...ich includes guidelines for countries to restrict ...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2American Chemical Society Awards John R Engen for Scientific Achievements 55858 1American Chemical Society Awards John R Engen for Scientific Achievements 55858 2American Chemical Society Awards John R Engen for Scientific Achievements 55858 3New Medical Technology Company CareFusion Spins Off From Cardinal Health Begins Trading on NYSE 55856 1New Medical Technology Company CareFusion Spins Off From Cardinal Health Begins Trading on NYSE 55856 2Cardinal Health Completes Spinoff of CareFusion Corp 55853 1Cardinal Health Completes Spinoff of CareFusion Corp 55853 2Cardinal Health Completes Spinoff of CareFusion Corp 55853 3
...s being told their children have peanut allergies ...t peanuts safely, a study by researchers at the Un...dren,s Hospital has found. , Peanut allergies occu...sian Society of Clinical Immunology and Allergy. ...Brynn Wainstein, a Sydney Children,s Hospital immu...
...and least studied freshwater turtles has been foun...he threatened species can be saved from extinction...), World Wildlife Fund (WWF), the Cambodian Fisher...rvation Team captured and released an 11-kilogram...le (Pelochelys cantorii) during a survey in March....
...Great Lakes and neighboring waterways is approachi... Cornell professor of aquatic animal medicine in t...rhagic septicemia virus (VHSV), which causes anemi...d in 19 species and poses a potential threat to Ne...t’s pretty obvious this is an epidemic even if it ...
Other Biology News:Peanut allergies overstated, study finds 2Rare soft-shell turtle, nesting ground found in Cambodia 2Rare soft-shell turtle, nesting ground found in Cambodia 3Cornell lab confirms deadly fish virus spreading to new species 2
Corning Roller Bottle Easy Grip Caps, Sterile from Sigma-Aldrich
Affymetrix Standard Data Analysis Report from Asuragen, Inc.
CORNING ROLLER BOTTLE, 850CM2, PS, EASY GRIP CAP, GRADUATED from Sigma-Aldrich
DKW/Juglans Basal Salt Mixture from Sigma-Aldrich
Biology Products: